These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9928118)

  • 1. Thrombolytic effect after sequential double-bolus administration of tissue plasminogen activator and urokinase-fibrinogen conjugate into dogs with venous thrombosis.
    Maksimenko AV; Tischenko EG; Golubykh VL
    Ann N Y Acad Sci; 1998 Dec; 864():409-17. PubMed ID: 9928118
    [No Abstract]   [Full Text] [Related]  

  • 2. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
    Maksimenko AV; Tischenko EG
    J Thromb Thrombolysis; 1999 Jun; 7(3):307-12. PubMed ID: 10373713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR; Lijnen HR; Stassen JM; Collen D
    Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-arterial prourokinase for acute ischemic stroke.
    Akins PT
    JAMA; 2000 Apr; 283(16):2102; author reply 2103-4. PubMed ID: 10791495
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen].
    Maksimenko AV; Tishchenko EG; Petrova ML; Golubykh VL
    Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion.
    Valji K
    J Vasc Interv Radiol; 2000 Apr; 11(4):411-20. PubMed ID: 10787198
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.
    Guerrero B; Arocha-Piñango CL; Pinto MA; Müller CA; Gil San Juan AG; Amorim S; Perales J
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):521-9. PubMed ID: 11685039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic thrombolysis for cerebral venous and dural sinus thrombosis: a systematic review.
    Viegas LD; Stolz E; Canhão P; Ferro JM
    Cerebrovasc Dis; 2014; 37(1):43-50. PubMed ID: 24356180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 12. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile.
    Maksimenko AV
    Ann N Y Acad Sci; 1998 Dec; 864():96-105. PubMed ID: 9928084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous or intra-arterial thrombolysis?: it's time to find the right approach for the right patient.
    Mattle HP
    Stroke; 2007 Jul; 38(7):2038-40. PubMed ID: 17540964
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
    Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
    Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
    Motomiya T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
    [No Abstract]   [Full Text] [Related]  

  • 17. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
    Gurewich V
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-arterial thrombolysis of complete deep cerebral venous thrombosis.
    Liebetrau M; Mayer TE; Bruning R; Opherk C; Hamann GF
    Neurology; 2004 Dec; 63(12):2444-5. PubMed ID: 15623729
    [No Abstract]   [Full Text] [Related]  

  • 19. Intra-arterial thrombolysis.
    American Society of Interventional and Therapeutic Neuroradiology
    AJNR Am J Neuroradiol; 2001 Sep; 22(8 Suppl):S18-21. PubMed ID: 11686069
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
    Grunwald MR; Hofmann LV
    J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.